Pit-1 CRISPR Activation Plasmid (h): sc-401671-ACT

Human POU1F1 encodes the pituitary-specific POU-homeodomain transcription factor Pit-1, a central regulator of anterior pituitary lineage specification and endocrine gene expression. Pit-1 binds conserved promoter and enhancer elements to control transcriptional programs required for somatotroph, lactotroph, and thyrotroph development, coordinating with co-regulators and chromatin remodeling complexes to shape cell identity. This axis integrates pituitary developmental signaling and hormone synthesis pathways by modulating key target genes including GH1, PRL, and TSHB. Dysregulation or pathogenic variants in POU1F1 are linked to pituitary hormone deficiencies and congenital hypopituitarism, making Pit-1 a widely used model for studying endocrine differentiation and transcriptional network control.

Pit-1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous POU1F1 expression without altering the underlying DNA sequence.

Pit-1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the POU1F1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the POU1F1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Pit-1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native POU1F1 locus and enabling the study of Pit-1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Pit-1 pathway restoration in tumor cells with silenced or reduced POU1F1 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.